1. Therapeutic Effects of FK506 on IgA Nephropathy Rat
- Author
-
Zhaoyang Duan, Yan Du, Zhao Chen, Lining Jia, Zhian Lv, Ganglian Yao, Li Wang, Jiamei Lu, Rongguo Fu, Linting Wei, Lifang Tian, Fengming Dong, and Xiaotao Ma
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,lcsh:Diseases of the circulatory (Cardiovascular) system ,TRPC ,MAP Kinase Signaling System ,medicine.medical_treatment ,H&E stain ,Gene Expression ,urologic and male genital diseases ,lcsh:RC870-923 ,Tacrolimus ,Nephropathy ,03 medical and health sciences ,medicine ,lcsh:Dermatology ,Animals ,Phosphorylation ,Hematuria ,TRPC Cation Channels ,Proteinuria ,ERK1/2 ,business.industry ,Calcineurin ,Glomerulonephritis, IGA ,General Medicine ,IgA nephropathy ,lcsh:RL1-803 ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,Rats ,030104 developmental biology ,Immunosuppressive drug ,Nephrology ,lcsh:RC666-701 ,Fk506 ,Immunohistochemistry ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Immunosuppressive Agents ,Kidney disease - Abstract
Background/Aims: FK506 is an immunosuppressive drug and a calcineurin inhibitor that has been widely used in kidney disease in recent years. FK506 shows a wide range of biological and pharmaceutical effects; however, the mechanism of its anti- proliferative effect has not been well elucidated. An IgA nephropathy (IgAN) model was used to generate a mesangial cell proliferation model. This study aims to examine the effect of FK506 on IgAN rats and the underlying mechanisms. Methods: Hematuria, proteinuria and renal function were measured. To observe the pathological conditions, we performed HE (hematoxylin - eosin) and PAS (periodic acid - schiff) staining. Transcription and protein expression levels were detected by qRT - PCR (quantitative real-time polymerase chain reaction) and Wb (western blotting). The location and semi-quantitative expression levels of TRPCs, CaN (Calcineurin) and α-SMA were examined by IHC (Immunohistochemical staining). Results: We found that FK506 could improve hematuria, proteinuria and renal function, especially in the HF (high-dose FK506) groups. Renal pathological changes were ameliorated in the treatment groups. FK506 could significantly decrease TRPCs, CaN, phosphorylation of ERK1/2 and α-SMA expression. Conclusion: Taken together, these results suggest that the therapeutic effect of FK506 on IgAN might be partially associated with the down-regulated expression of TRPC channels, CaN and phosphorylation of ERK1/2.
- Published
- 2017